

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all previously presented claims.

1. (Currently Amended) A method of treating pouchitis in a human in need thereof, comprising administering to said human a pharmaceutical composition suitable for rectal use, wherein said composition comprises ~~an~~the antisense oligonucleotide of SEQ ID NO: 1.
2. (Original) The method of Claim 1, wherein said composition is an enema.
3. (Original) The method of Claim 1, wherein said composition is a suppository.
- 4-6. (Cancelled)
7. (Original) The method of Claim 1, wherein said composition further comprises a penetration enhancer.
8. (Original) The method of Claim 7, wherein said penetration enhancer is a surfactant, fatty acid, bile salt, chelating agent or non-chelating non-surfactant.
9. (New) The method of Claim 1, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
10. (New) The method of Claim 9, wherein the modified internucleoside linkage is a phosphorothioate linkage.
11. (New) The method of Claim 1, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
12. (New) The method of Claim 11, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
13. (New) The method of Claim 1, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.
14. (New) The method of Claim 13, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
15. (New) The method of Claim 1, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
16. (New) The method of Claim 15, wherein the modified nucleobase is a 5-methylcytosine.

17. (New) The method of Claim 1, wherein the antisense oligonucleotide is in a salt form.
18. (New) A method of treating pouchitis in a human, comprising:  
selecting a human in need of treatment for pouchitis; and  
administering to said human a composition suitable for rectal use comprising the antisense oligonucleotide of SEQ ID NO: 1.
19. (New) The method of Claim 18, wherein said composition is an enema.
20. (New) The method of Claim 18, wherein said composition is a suppository.
21. (New) The method of Claim 18, wherein said composition further comprises a penetration enhancer.
22. (New) The method of Claim 18, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
23. (New) The method of Claim 18, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
24. (New) The method of Claim 18, wherein the antisense oligonucleotide comprises at least one modified nucleobase.